PAM
SRPT icon

Princeton Alpha Management’s Sarepta Therapeutics SRPT Stock Holding History

Princeton Alpha Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-9,106
Closed -$270K – 334
2017
Q1 		$270K Buy
+9,106
New +$282K 0.09% 380
2014
Q3 		– Sell
-9,378
Closed -$279K – 814
2014
Q2 		$279K Buy
+9,378
New +$296K 0.06% 462

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Princeton Alpha Management's SRPT Position: Q2 2017 in Review

Princeton Alpha Management sold out of Sarepta Therapeutics (SRPT) in Q2 2017, closing a stake of 9,106 shares — an estimated $270K sold.

Princeton Alpha Management first reported a position in SRPT in Q2 2014 and held it in 2 quarters. The position peaked at $279K in Q2 2014. 189 funds tracked by Wall St. Rank hold SRPT as of Q2 2017.

  • Princeton Alpha Management reported no remaining Sarepta Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Princeton Alpha Management sold 9,106 Sarepta Therapeutics shares in Q2 2017, an estimated $270K.
  • Princeton Alpha Management first reported a position in Sarepta Therapeutics in Q2 2014 and held it in 2 quarters.
  • Princeton Alpha Management's Sarepta Therapeutics position peaked at $279K in Q2 2014.
  • 189 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2017.

Based on Princeton Alpha Management's 13F filing for Q2 2017.